Humanwell Healthcare's (SHA:600079) unit, Yichang Humanwell Pharmaceutical, will conduct clinical trials on HW231019 tablets after receiving approval from China's drug administration, according to a Shanghai Stock Exchange filing on Wednesday.
The drug will be tested as a treatment for acute pain, the filing said.
The pharmaceutical company spent approximately 20 million yuan into the research and development of the drug.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。